Skip to content
TrialScanner

NCT02730312

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Phase 1CompletedXNCRLead

Registry record

Lead sponsor
Xencor, Inc.
Conditions
Acute Myelogenous Leukemia; B-cell Acute Lymphoblastic Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Chronic Myeloid Leukemia, Blast Crisis
Primary completion
Sep 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02730312 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02730312: PH 1 Study to Evaluate... | TrialScanner